Bisoprolol and bisoprolol-valsartan compatibility studied by differential scanning calorimetry, nuclear magnetic resonance and X-ray powder diffractometry. by Skotnicki,  Marcin et al.
Durham Research Online
Deposited in DRO:
20 May 2015
Version of attached ﬁle:
Published Version
Peer-review status of attached ﬁle:
Peer-reviewed
Citation for published item:
Skotnicki, Marcin and Aguilar, Juan A. and Pyda, Marek and Hodgkinson, Paul (2015) 'Bisoprolol and
bisoprolol-valsartan compatibility studied by diﬀerential scanning calorimetry, nuclear magnetic resonance and
X-ray powder diﬀractometry.', Pharmaceutical research., 32 (2). pp. 414-429.
Further information on publisher's website:
http://dx.doi.org/10.1007/s11095-014-1471-7
Publisher's copyright statement:
c© The Author(s) 2014. This article is published with open access at Springerlink.com. This article is distributed under
the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
Additional information:
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-proﬁt purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom
Tel : +44 (0)191 334 3042 | Fax : +44 (0)191 334 2971
http://dro.dur.ac.uk
RESEARCH PAPER
Bisoprolol and Bisoprolol-Valsartan Compatibility Studied
by Differential Scanning Calorimetry, Nuclear Magnetic
Resonance and X-Ray Powder Diffractometry
Marcin Skotnicki & Juan A. Aguilar & Marek Pyda & Paul Hodgkinson
Received: 27 April 2014 /Accepted: 24 July 2014 /Published online: 13 August 2014
ABSTRACT
Purpose The objective of this study was to evaluate the thermal
behavior of crystalline and amorphous bisoprolol fumarate and its
compatibility with amorphous valsartan. This pharmacologically
relevant drug combination is a potential candidate for fixed-dose
combination formulation.
Methods DSC and TMDSC were used to examine thermal
behavior of bisoprolol fumarate. SSNMR and XRPDwere applied
to probe the solid state forms. The thermal behavior of physical
mixtures with different concentrations of bisoprolol and valsartan
were examined by DSC and TMDSC, and the observed interac-
tions were investigated by XRPD, solution- and solid-state NMR.
Results The phase transitions from thermal methods and solid-
state NMR spectra of crystalline and amorphous bisoprolol fuma-
rate are reported. Strong interactions between bisoprolol fuma-
rate and valsartan were observed above 60 C, resulting in the
formation of a new amorphous material. Solution- and solid-state
NMR provided insight into the molecular nature of the
incompatibility.
Conclusions A combined analysis of thermal methods, solution-
and solid-state NMR and XRPD experiments allowed the inves-
tigation of the conformational and dynamic properties of
bisoprolol fumarate. Since bisoprolol fumarate and valsartan react
to form a new amorphous product, formulation of a fixed-dose
combination would require separate reservoirs for bisoprolol and
valsartan to prevent interactions. Similar problems might be ex-
pected with other excipients or APIs containing carboxylic groups.
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ABBREVIATIONS
ACE Angiotensin-converting enzyme
API Active pharmaceutical ingredient
BCS Biopharmaceutics classification system
BISO Bisoprolol fumarate
COSY Correlated spectroscopy
CP Cross-polarization
CVD Cardiovascular disease
DBPPSTE DOSY bipolar gradient pulses stimulated echo
sequence
DE Direct excitation
DOSY Diffusion ordered spectroscopy
DSC Differential scanning calorimetry
FDC Fixed-dose combination
FT-IR Fourier transform infra-red spectroscopy
HMBC Heteronuclear multiple bond correlation
HSQC Heteronuclear single quantum correlation
MAS Magic-angle spinning
MCCP Multicomponent cardiovascular pill
PVP-CL Cross-linked polyvinylpyrrolidone
SSNMR Solid-state nuclear magnetic resonance
TGA Thermogravimetric analysis
TMDSC Temperature-modulated DSC
VAL Valsartan
XRPD X-ray powder diffractometry
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INTRODUCTION
Cardiovascular diseases (CVDs), such as coronary heart dis-
ease, heart failure, cerebrovascular disease or hypertension,
are the major cause of death in developed countries (1).
Bisoprolol fumarate (BISO), or (RS )-1-( (alpha-(2-
isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-
propanol fumarate (2:1), Fig. 1a, is a beta1-selective
(cardioselective) adrenoceptor blocking agent (2). Valsartan
(VAL), or N-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-N-valeryl-L-
valine, Fig. 1b, is a potent, highly specific angiotensin II type 1
(AT1) receptor antagonist (3). Both agents are used in the
management of hypertension and heart failure (2, 3). Both
are administered orally in a capsule or tablet form andmay be
used alone or in combination, but there is no single dosage
form currently on the market containing both bisoprolol and
valsartan. Combining drugs with synergistic mechanism of
action in one dosage form (fixed-dose combination, FDC)
has potential benefits, such as improved efficacy, reduced
dosing, lower cost or enhanced patient compliance (4). Com-
bination therapy has been shown to reduce CVD complica-
tions by more than 80% (4), and strong interest has been
expressed by the pharmaceutical industry to develop an all-
in-one pill (multicomponent cardiovascular pill, MCCP or
polypill) containing an angiotensin-converting enzyme (ACE)
inhibitor, beta-blocker, aspirin and statin (5). Both bisoprolol
and valsartan (as an alternative for an ACE inhibitor) are good
candidates for a two-ingredient FDC or MCCP.
The simplest and the most economic approach to formu-
lating a multi-ingredient dosage form is a blend or granulation
containing all the active pharmaceutical ingredients (APIs).
The combination of different agents in a single dosage form
can, however, lead to interactions between APIs, potentially
affecting the stability and bioavailability of either component
(6–12). Such interactions, termed incompatibilities, can be
either physical or chemical in nature. Chemical interactions
between APIs are well documented for FDCs intended for the
treatment of tuberculosis, malaria or CVDs, conditions which
usually require combination therapy (10–15). For example,
ternary and quaternary drug combinations containing rifam-
picin and isoniazid along with pyrazinamide and/or etham-
butol hydrochloride were very unstable, showing up to 70 or
95% loss of rifampicin or isoniazid, respectively, due to chem-
ical reaction (11). Also, Kumar et al. reported incompatibility
between polypill ingredients – atenolol, lisinopril, aspirin and
statin due to chemical reactions (14, 15). Solid-state reactions
of API with excipient or API can include: transacylation,
Maillard browning reactions and acid–base reactions. As
one of the most frequent approaches to improve physico-
chemical properties of an ionisable compound is to form a
salt, and as formation of a free base/acid or new salt can
significantly change physicochemical properties, acid–base
reactions play an important role in formulation stability.
Rohrs et al. reported decrease in dissolution rate for tablets
of delavirdine mesylate following storage under accelerated
stability conditions. This was found to result from formation of
the less-soluble delavirdine free base due to acid–base reaction
with excipient (croscarmellose sodium), as confirmed by Fou-
rier transform infra-red spectroscopy (FT-IR) and solid-state
NMR (SSNMR) (16). Zannou et al. found that maleate salt of
a basic API showed a major loss in potency following stability
testing, which again was attributed to conversion of the salt to
the free base. The conversion strongly depended on
microenviromental pH, and the formulation was successfully
developed by acidification using citric acid as an excipient
(17). Guerrieri and Taylor investigated by FT-IR and Raman
spectroscopy four model pharmaceutical salts (two APIs mes-
ylate and napsylate salts) mixed with common basic excipients
Fig. 1 Chemical structures of (a) bisoprolol fumarate (M=766.96 g mol−1)
and (b) valsartan (M=435.52 g mol−1) with the carbons numbered. The
chemical structure of bisoprolol fumarate is that of the neutral molecules, as
conventionally given. Thematerial is, however, expected to be in a salt form as
a solid, with the fumaric acid present as a doubly de-protonated fumarate ion
and with the bisoprolol assumed to be protonated at its NH site.
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and exposed to moderate relative humidity (18). They found
that formation of free base depends on a number of factors
such as pHmax of the salts (the pH of a solution where there is
saturation of both ionized and unionized species), as well as
the free base solubility. The conversion was also affected by
excipient properties, including basicity, solubility, physical
state and surface area.
Even in the absence of chemical reactions between com-
ponents, the combination of two or more compounds (API-
API or API-excipient) can result in physical interactions such
as polymorphic transitions (19), amorphisation (20) or the
formation of eutectic mixtures (21, 22). These can cause
problems during manufacturing (22, 23), with shelf life (24)
or bioavailability (25). For example, Bristol-Myers Squibb in
2010–11 recalled over 60 million tablets of an FDC product,
Avalide®, containing an angiotensin receptor antagonist
(irbesartan) and a diuretic (hydrochlorothiazide) due to the
appearance of a less-soluble irbesartan polymorph (26). No
such problems were observed with products containing
irbesartan only. Zalac et al. have studied binary mixtures of
antipyretic/analgesic drugs paracetamol and propyphenazone
using differential scanning calorimetry (DSC), X-ray powder
diffractometry (XRPD) and FT-IR spectroscopy (22). Studies
revealed physical interactions related to eutectic formation
and a lower degree of crystallinity of both components in the
physical mixture, with the formation of eutectic mixture hav-
ing a significant impact on the physical stability of the formu-
lation. Rawlinson et al. studied interaction between cross-
linked polyvinylpyrrolidone (PVP-CL) and the poorly soluble
crystalline drug compound, ibuprofen, by DSC, XRPD, Ra-
man and FT-IR spectroscopy (20). They reported a reduction
in the crystallinity of ibuprofen observed by XRPD on simple
physical mixing with PVP-CL, with amorphisation increasing
during storage of the physical mixtures at ambient conditions.
Clearly the identification of possible interactions between
APIs is extremely important at an early stage of drug devel-
opment process. Thermal analysis is frequently used to study
the physicochemical properties of APIs and compatibilities
between drug-drug and drug-excipient (13, 22, 27, 28). DSC
quickly provides information about possible interactions
among the formulation components, according to the appear-
ance, shift or disappearance of phase transition peaks and/or
variations in the corresponding enthalpy or heat capacity
values in thermal curves of drug-drug/excipient in physical
mixtures (29, 30). However, the interpretation of the thermal
data is not always trivial, and the interactions observed at high
temperatures may not always be relevant to ambient condi-
tions. Therefore, the use of complementary analytical tech-
niques, such as XRPD or FT-IR, is advisable, as shown in
research papers (31, 32) and as reviewed in Ref. (33). Solid-
state nuclear magnetic resonance is another technique used to
characterize pharmaceuticals (34, 35) and study physical or
chemical interactions between APIs and excipients. It has
been successfully used for characterizing the physical interac-
tions occurring between API and polymers (36–39), between
API and β-cyclodextrin (40), and acid–base reactions between
API and excipients (16, 41, 42), but SSNMR has not been
widely used, however, in API–API compatibility studies.
Bisoprolol belongs to class I of the Biopharmaceutics Clas-
sification System (BCS) (high solubility and high permeability)
and is marketed in its crystalline form as a fumarate salt.
Valsartan belongs to class II BCS (low solubility and high
permeability) and is marketed in its amorphous form as a free
acid. The aim of this study was to examine the thermal
behavior of crystalline and amorphous bisoprolol fumarate
and its compatibility with amorphous valsartan, employing
thermogravimetric analysis (TGA), standard differential scan-
ning calorimetry, temperature-modulated DSC (TMDSC),
Fourier transform infra-red spectroscopy, solution- and
solid-state nuclear magnetic resonance and powder X-ray
diffractometry. The physicochemical properties of valsartan
were reported by us elsewhere (43).
MATERIALS AND METHODS
Materials
Pharmaceutical grade bisoprolol fumarate was obtained from
Biofarm, Poznań, Poland and used without further treatment.
The amorphous form of bisoprolol was prepared immediately
prior to experimental measurements in the DSC pan in the
instrument, in theNMR rotor in the probe, or on the hot stage
of XRPD by heating sample to 120°C, holding for 5 min and
then cooling with at least 10°C min−1 cooling rate to −50°C.
Attempts to obtain diffraction-quality crystals by recrystalliza-
tion from water, methanol, ethanol and ethyl acetate solutions
were unsuccessful.
Valsartan (form AR, as-received, pharmaceutical
grade) was obtained from Polpharma, Starogard
Gdański, Poland and used without further treatment.
Its fully amorphous form (form AM) was prepared im-
mediately prior to experimental measurements in DSC
pan in the instrument, in the NMR rotor in the probe,
or on the hot stage of XRPD by heating sample to
140°C, holding for 20 min then cooling with at least
approximately 3°C min−1 cooling rate to room
temperature.
The purity of the provided materials was verified by solu-
tion 1H and 13C NMR. Physical mixtures of bisoprolol/
valsartan in different concentrations from 10 to 95% (w/w)
were prepared by mixing in a glass mortar for 20 min. Sam-
ples were used within 12 h.Melts were produced by heating of
binary mixtures in situ in the DSC furnace, NMR probe or on
the XRPD holder. The samples were melted at 120°C and
cooled to −50°C with at least 10°C min−1 cooling rate.
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THERMOGRAVIMETRIC ANALYSIS
TGA curves were obtained using a Mettler-Toledo TGA/
DSC1 instrument or a Perkin Elmer Pyris 1 TGA instru-
ment under a nitrogen gas flow 60 mL min−1. About
2 mg mass of powder samples were placed in an opened
ceramic pan and heated at a rate of 10°C min−1 from 25
to 600°C.
DIFFERENTIAL SCANNING CALORIMETRY
DSC curves were obtained using a DSC Q1000 TA Instru-
ment Inc. (V9.9 Build 303) or a DSC 821 Mettler-Toledo
instrument under a nitrogen gas flow of 50 and 60 mL min−1,
respectively. Sample powders (1–10 mg) were crimped in a
standard or hermetic aluminium pan and heated with differ-
ent rates (1, 5 or 10°C min−1) from −50 to 140°C. Next, the
samples were cooled down at 10, 20 or 50°C min−1 to room
temperature and reheated to 140°C in a second run.
TMDSC curves were obtained using the DSC Q1000 TA
Instrument Inc. instrument with an underlying heating rate
1°C min−1 and a temperature modulation with amplitude of
0.5°C and period of 60 s (which is sometimes termed “stan-
dard TMDSC”) from −50 to 140°C. The samples were then
cooled at 10, 20 or 50°Cmin−1 to−50°C without modulation
and reheated to 140°C in a second run.
The equipment was calibrated with indium (m. p. =
156.65°C, ΔHf=28.45 J g
−1), and at least two tests were run
on each sample. Melting, crystallisation and relaxation events
are quoted as an onset temperature. Glass transition temper-
atures are quoted as midpoints. All values were determined
using TA Universal Analysis 2000 V4.5A or Mettler-Toledo
Stare SW V10.0 software. Errors are quoted as one standard
deviation.
NUCLEAR MAGNETIC RESONANCE
Solution-state NMR experiments were carried out on a
Varian VNMRS-700 machine with 1H and 13C fre-
quencies of 699.73 and 175.97 MHz, respectively. Spec-
tra of bisoprolol samples were measured in 0.5 mL of
D2O and [D6]-DMSO. Spectra of valsartan and physi-
cal mixtures with bisoprolol were measured in 0.5 mL
of [D6]-DMSO. All measurements were performed at
25°C. The diffusion ordered spectroscopy (DOSY) ex-
periments were measured at 25°C on a 600 MHz
Agilent spectrometer equipped with a probe with a z-
gradient coil. The DBPPSTE (DOSY bipolar gradient
pu l se s s t imula ted echo sequence ) convec t ion-
compensated pulse sequence was used (44, 45) to ac-
quire data sets in 31 min with 32 gradient amplitudes
ranging from 5 to 45 G cm−1 in equal steps of gradient
squared, using 32 transients, a total diffusion-encoding
gradient duration of 2.0 ms, and a diffusion time of
200 ms.
Carbon-13 solid-state NMR spectra were generally record-
ed with cross-polarization (CP) and magic-angle spinning
(MAS) using Varian VNMRS 400 and Varian Infinity Plus
500 spectrometers, operating at a 13C frequency of 100.56 and
125.68 MHz, respectively. Probes using 5 and 6 mm diameter
rotors made of zirconia were employed. Typical operating
conditions used a CP contact time of 2 ms, a recycle delay of
2 s, 512 to 2048 transients and spin rate of 10 kHz. Carbon
chemical shifts were referenced to the signal for
tetramethylsilane via a replacement sample of solid
adamantane (δC=38.4 ppm for the high-frequency line).
Variable-temperature experiments were performed from
−20 to 120°C, allowing samples to stabilize for 15–20 min
before starting acquisition. All of the temperatures shown for
13C SSNMR experiments are quoted with a correction of +
16°C above the displayed temperature, which is the estimated
increase in sample temperature for a 5 mm rotor spinning at
10 kHz, based on previous calibration experiments using lead
nitrate (46). While the VT measurements are reproducible
(performed at least in duplicate), and relative temperatures
are accurate to within ±1°C, the uncertainty on the absolute
temperatures is estimated at ±4°C. The very different sample
conditions in the different techniques used, in any case, limits
the transferability of temperature scales. Spinning sidebands
were identified with the aid of spectra acquired with 14 kHz
spinning rate.
Proton spectra were recorded using Varian Infinity Plus
500 spectrometer operating at a 1H frequency of
499.70 MHz. A Bruker MAS probe using 1.3 mm diameter
zirconia rotors was employed. Spectra were typically acquired
using a recycle delay of 2 s, 4 to 64 transients and spin rates of
43 and 53 kHz. Data was also acquired at longer recycle
delays (10 s) to verify that signals associated with slowly
relaxing protons were not being missed. The estimated in-
crease of the sample temperature with MAS rate of 53 kHz is
estimated to be about 25°C; identical results (but with lower
spectral resolution) were obtained at the lower spin rate.
Proton broadline NMR spectra for static samples were mea-
sured at 400.17 MHz using a Bruker Avance III HD spec-
trometer. A MAS probe using 5 mm diameter rotors made of
zirconia was employed. A recycle delay of 5 s was used and 32
transients were acquired. Spectra were measured over a tem-
peratures range from 25 to 120°C, allowing at least 20min for
stabilization before acquisition.
Data were processed using gsim (47). A Gaussian line
broadening of 40 Hz was applied to the 13C spectra
and a “resolution enhancement” corresponding to an
80 Hz Gaussian function was applied to the 1H MAS
spectra.
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POWDER X-RAY DIFFRACTOMETRY
X-ray diffraction patterns for most samples were obtained
with a Bruker D8 ADVANCE instrument using a graphite
bent-crystal monochromator (Cu Kα). Samples were placed
on a hot-stage sample holder and scanned in reflection mode
from 10 to 40° 2θ over a temperatures range from 0 to 120°C.
Samples were allowed to stabilize for 10–15 min before
starting acquisition.
RESULTS
Thermal Analysis
Figure 2 shows the standard DSC traces of crystalline
bisoprolol with 10°C min−1 heating rate, cooling the sample
to −50°C at 10°C min−1 and a second heating. On the first
heating, the DSC curve shows one sharp endothermic peak
with an onset at 102.3±0.3°C and an enthalpy of fusion
ΔHBISO=110±2 J g
−1 due to melting. Three events are
observed on the second run: a glass transition at −3.6±
0.9°C with a change of heat capacity (ΔCp) of 0.51±
0.02 J g−1 K−1, followed by a cold crystallization exotherm
at 24.2±0.6°C (ΔH=39±2 J g−1) and a melting peak with
onset at 95.4±1.4°C (ΔH=85±1 J g−1). The lower values of
the melting temperature and ΔH in the second heating may
be due to differences in morphology in the re-crystallized
phase of sample compared to the original crystalline material.
There may be nanocrystalline domains present in the re-
crystallized sample, which can lower the peak of melting,
and/or the re-crystallization of the amorphous material may
be incomplete. Both starting and re-crystallized material
showed birefringence under polarized light microscopy,
confirming their crystalline nature.
The previously reported (43) standard DSC curves of
valsartan (form AR) show two endothermic events, one at
around 60–90°C (ΔH=5±1 J g−1) corresponding to a loss of
water / adsorbed solvent, and a second event with onset at
98.2±0.9°C (ΔHVAL=26±2 J g
−1) corresponding to an en-
thalpy relaxation peak overlapped with a change of heat
capacity. On the second heating run only one event is ob-
served: a glass transition 73.9±0.5°C and ΔCp=0.49±
0.01 J g−1 K−1.
TGA curves (Figure 1S, supplementary material) of the
individual components and a 50/50 (w/w) bisoprolol/
valsartan (form AR) physical mixture show that the ingredi-
ents change individually in the mixture, indicating that no
degradation due to interaction of the components takes place.
However, the DSC curve of the same physical mixture, Fig. 3,
does not show the expected sharp bisoprolol melting peak and
instead shows overlapped broad endothermic peaks at around
60–100°C, indicating some physical or chemical interaction
has disrupted the crystal lattice of bisoprolol. The total enthal-
py of this peak is estimated to be 51±5 J g−1, which is lower
than the weighted sum of the enthalpies of the individual
components, (ΔHBISO+ΔHVAL)/2≈68 J g−1, suggesting inter-
action. Two minima at about 77 and 100°C are observed.
The peak with minimum at around 100°C can be ascribed to
the enthalpy relaxation peak of valsartan (form AR). This is
confirmed by the DSC trace of a physical mixture made with
freshly prepared amorphous valsartan (form AM), which
shows only the broad peak with one minimum at 77°C,
confirming that the peak at 100°C arises from valsartan (form
AR). The interaction observed by DSC is also seen in a simple
micro- and macroscopic observation; powder samples mixed
and heated on the hot-stage to about 60°C convert into a
more viscous state, and the material becomes sticky.
TMDSC was employed to separate the kinetic and ther-
modynamic processes during heating for a selected number of
samples. The total heat flow in a DSC experiment is the sum
Fig. 2 Standard DSC curves of crystalline bisoprolol showing 1st heating,
cooling (glass transition of amorphised material) and 2nd heating (glass tran-
sition, cold crystallisation, melting of re-crystallised material). All runs obtained
at a 10°C min−1 heating rate.
Fig. 3 Standard DSC curves of the APIs and their 50/50 physical mixtures.
The broad endothermic peak in the mixture indicates a significant physical or
chemical interaction. All runs obtained at a 10°C min−1 heating rate
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of the heat flow associated with the sample’s heat capacity and
a second term associated with physical or chemical transfor-
mations (48, 49). By imposing a time-dependent modulation
on the temperature ramp, time-dependent DSC decomposes
the overall heat flow in a reversing and non-reversing heat-
flow rate, corresponding to “thermodynamic” and kinetically
limited processes, respectively. Figure 4a shows the reversing
and non-reversing heat-flow rates obtained from TMDSC as
a function of temperature for the pure components and phys-
ical mixtures in 80/20, 50/50 and 20/80 (w/w) ratios.
TMDSC separates the relaxation enthalpy of valsartan, ob-
served in the non-reversing signal, from the change in heat
capacity at glass transition observed in the reversing signal.
The non-reversing curves for the 20/80 and 50/50 physical
mixtures (solid lines) clearly show the enthalpy relaxation peak
ascribed to valsartan (form AR) and a broad endotherm most
probably due to physical or chemical change of bisoprolol
fumarate. The enthalpy relaxation in the mixtures is difficult
to estimate precisely due to peak overlap, but the values are
approximately 70 and 50% lower than expected (ΔH50%VAL
~4 J g−1 compared to 50% ΔHVAL=13 J g
−1, and ΔH80%VAL
~11 J g−1 compared to 80% ΔHVAL=21 J g
−1). It was not
possible to estimate the value of enthalpy relaxation for the
80/20 mixture. The reversing curves of the physical mixtures,
dashed lines in Fig. 4a, show only one event i.e. the glass
transition. It is clear that there is a change in the glass transi-
tion temperature of valsartan in the 50/50 and 80/20 physical
mixtures, and in its heat capacity in all mixtures. Standard
DSC experiments performed for twelve physical mixtures
from 0 to 100% of bisoprolol show the same behaviour
Fig. 4 (a) 1st and (b) 2nd heating TMDSC experiments. Reversing (dashed line) signals show changes in glass transition and heat capacities. Non-reversing (solid
line) signals show changes due to bisoprolol-valsartan interaction and enthalpy relaxation of valsartan (form AR), cold crystallization of bisoprolol, enthalpy
relaxation of co-amorphous mixtures and valsartan (form AM).
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(Figure 2S, supplementary material) as observed in TMDSC
on the selected samples. In the physical mixtures with 90%
bisoprolol by weight, the melting peak is broadened but can
still be observed, while the melting peak was not identified
with 80% or less bisoprolol in the mixture.
In the second heating of the physical mixtures, both com-
ponents are amorphous. The TMDSC reversing curves of
quench-cooled bisoprolol, Fig. 4b, show two thermodynamic
processes: the glass transition and melting. As expected, the
kinetically hindered cold crystallization process appears on the
non-reversing curve. Neither melting nor cold crystallization is
observed for co-melted 50/50 physical mixture; only a glass
transition is observed. Compounds that are not miscible
would show two separate glass transitions, one for each com-
pound, while the co-melted bisoprolol/valsartan mixture only
shows a single glass transition (Tg=35.9°C) at a temperature
intermediate between the Tg of pure drugs, with the temper-
ature depending on the composition. These findings suggest
that valsartan and bisoprolol had dissolved each other to form
a homogenous amorphous mixture (50). Bisoprolol effectively
lowers the Tg of valsartan, thus affecting its stability.
NMR and XRPD Analyses
While DSC provides macroscopic information about the in-
teraction between bisoprolol and valsartan, NMR and XRPD
were used to probe the molecular basis for this behavior.
Figure 5 shows the 13C solution-state spectrum of
bisoprolol and 13C CP MAS NMR spectra of crystalline and
quench-cooled (amorphous) bisoprolol. Due to the instability
of the amorphous form at room temperature, spectra for both
solid forms were acquired at −20°C i.e. below the glass
transition temperature. Standard NMR techniques (COSY,
HSQC and HMBC) were used to assign the solution-state
spectrum. The solid-state spectrum was assigned using
solution-state NMR data and spectral editing techniques:
interrupted decoupling (dipolar dephasing) and depolariza-
tion experiments (inversion times from 25 to 100 μs). The
resulting assignments are presented in Table I. The assign-
ment of the solid-state spectra contains ambiguities due to its
lower resolution and the differences in chemical shifts between
the solution and solid state. Some of these ambiguities could,
in principle, be resolved by computational prediction of chem-
ical shifts given a crystal structure (51), but they are not
significant for this study. Only one signal is observed for each
site of bisoprolol and the two chemically distinct sites of the
fumarate ion, indicating that the asymmetric unit cell contains
a single bisoprolol molecule and a half molecule of fumarate.
The spectrum of the crystalline material shows a set of low
intensity signals, denoted by arrows in Fig. 5. Since there is no
evidence from solution-state NMR of corresponding levels of
chemical impurities, these signals could potentially arise from
a second polymorphic form, or, more probably, enantiomeric
“defects” (e.g. a R-molecule occupying a site otherwise occu-
pied by S molecules). The low level of these signals (corre-
sponding to about 1% of material) prevents further charac-
terization. The spectrum of the quench-cooled form exhibits
the expected general broadness of the resonances due to the
range of local environments. These spectra vary slightly
from experiment to experiment, presumably reflecting
differences in cooling rates used to obtain the amorphous
form. Standard NMR techniques were used to assign the
solution-state spectrum of valsartan. The solid-state spectrum
assignment was done based on solution-state data and by
Fig. 5 (a) 13C solution-state NMR spectrum of bisoprolol in D2O at 25°C,
13C CPMAS NMR spectra of (b) crystalline and (c) quench-cooled (amor-
phous) bisoprolol at −20°C. Asterisks (*) denote spinning sidebands. Arrows
(↓) denote signals that are thought to arise from polymorphic or enantiomeric
impurities.
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computational prediction of chemical shifts. Detailed solid-
state NMR studies of pure valsartan will be published
separately.
Figure 6a–e shows 13C CP MAS spectra of crystalline
bisoprolol as a function of temperature. At low temperature,
distinct signals are observed for the phenyl carbons (C-9 and
C-11) at 113.0 and 119.3 ppm, indicating that the two halves
of the phenyl ring are not related by symmetry in the crystal
structure. The phenyl resonances coalescence (at 116.0 ppm)
above 60°C, corresponding to increasedmolecular mobility of
phenyl ring. This is commonly observed in molecular solids
e.g. Ref. (52) and references therein. Carbon C-8 and C-12
exhibit similar behavior, although this is not clearly resolved
due to overlap with the C-7 resonance. Subtle changes in the
isopropyl signals (C-1, C-2, C-17 and C-18) are also observed,
which are also consistent with increasing local mobility as the
sample warms.
Figure 6f shows the 13C CP MAS NMR spectrum of
bisoprolol heated above the melting point (to 120°C) and
cooled to 80°C, above both the glass transition and re-
crystallization temperatures. The much sharper spectrum is
consistent with the sample being in a rubbery state, with a high
degree of molecular mobility. As would be expected, the
phenyl ring and isopropyl methyl carbon resonances are av-
eraged in this state.
Figure 6g–j shows variable-temperature 13C spectra of
quench-cooled bisoprolol. As discussed above, the spectrum
of quench-cooled bisoprolol at −20°C is broad due to its
glassy nature. At 10°C, above the glass transition but below
the cold crystallization temperature, the spectrum is slightly
more resolved and sharper than at −20°C, consistent with
increased mobility and hence motional averaging in the rub-
bery state. The appearance of relatively narrow signals at 60
and 80°C shows that the bisoprolol has re-crystallized (35).
Figure 7 shows the 13C NMR spectra of bisoprolol,
valsartan and 70/30 and 50/50 physical mixtures at 38 and
80°C. The spectra at 38°C correspond to appropriately
weighted combinations of the spectra of the pure drugs,
showing no evidence of interactions between the components
at ambient temperature. There are changes in the aromatic
region (C-9, C-11) for the 70% bisoprolol/valsartan mixture,
implying increased molecular mobility of phenyl ring. This
observation is puzzling, and may simply reflect a strong sen-
sitivity of this spectral feature to sample temperature. The
spectrum of the 50/50 (w/w) physical mixture changes signif-
icantly at 80°C, Fig. 7h, with the peaks associated with the
bisoprolol having much lower intensities. There are also some
subtle changes in the valsartan resonances, e.g. some sharp-
ening of the methyl carbon (C-1), suggesting an increase in
mobility, and a slight decrease in intensity of C-11, but these
Table I Solution- and solid-state NMR chemical shifts for bisoprolol and 50/50 (w/w) bisoprolol/valsartan physical mixture at 25°C (solution-state) and 38°C
(solid-state).
Carbon
No
Bisoprolol Bisoprolol/valsartan (after heating to 80°C)
1H solution-state
NMR / ppm
(D2O)
1H solution-state
NMR / ppm
([D6]-DMSO)
13C solution-
state NMR /
ppm (D2O)
13C solution-
state NMR /
ppm ([D6]-DMSO)
13C CPMAS
NMR / ppm
1H solution-
state NMR / ppm
([D6]-DMSO)
13C solution-state
NMR / ppm
([D6]-DMSO)
17, 18 1.22 (dd, 12H) 1.12 (dd, 12H) 17.79, 18.21 20.48, 20.82 18.4, 19.9, 20.6, 23.3 1.21 18.61, 18.62,
19.19, 19.21a
1, 2 1.03 (d, 12H) 1.06 (d 12H) 20.93 22.49 1.06 22.48
15 3.10, 3.18
(2dd, 4H)
2.77, 2.92
(2dd, 4H)
46.63 48.65 51.2 2.93, 3.08 47.26, 47.28a
16 3.37 (sep, 2H) 3.04 (sep, 2H) 50.99 49.42 3.27 50.15
14 4.18 (m, 2H) 4.03 (m, 2H) 65.56 66.76 64.8 (CH2), 66.5 (CH),
67.8, 70.2 (CH2),
72.9, 73.6 (CH2)
4.12 65.57, 65.58a
4 3.51 (m, 4H) 3.46 (m, 4H) 66.45 67.18 3.47 67.20
5 3.51 (m, 4H) 3.46 (m, 4H) 68.79 69.57 3.47 69.60
13 3.95, 4.03 (2d, 4H) 3.92 (m, 4H) 69.46 70.76 3.93 70.29
6 4.39 (s, 4H) 4.38 (s, 4H) 72.19 72.11 4.38 72.09
3 3.58 (sep, 2H) 3.52 (sep, 2H) 72.49 71.27 3.52 71.28
9, 11 6.90 (d, 4H) 6.90 (d, 4H) 114.65 114.67 113.1; 119.2 6.88, 6.90a 114.38
8, 12 7.25 (d, 4H) 7.22 (d, 4H) 130.24 129.59 131.8, 133.1b 7.22 129.59
7 – – 130.32 131.02 130.4 – 131.23
20, 21 6.37 (s, 2H) 6.39 (s, 2H) 135.26 136.07 138.6 6.53 135.16
10 – – 157.79 158.34 158.7 – 158.13
19, 22 – – 174.51 169.73 175.1 – 167.83
a Resolution of signals most likely due to chiral centre and it is the subject of ongoing independent investigation. b At −20°C
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are difficult to interpret with confidence. In contrast to the
DSC results, there are no significant changes observed at
80°C for the 70/30 and 80/20 physical mixtures in compar-
ison to the pure drugs (data not shown).
Figure 7d shows the spectrum of the 50/50 (w/w) physical
mixture of bisoprolol/valsartan heated to 80°C and then
cooled to 38°C. The spectrum at 38°C is similar to the
spectrum at 80°C, i.e. the reduction in intensities of the peaks
associated with crystalline bisoprolol is irreversible. Experi-
ments using longer recycle delays (up to 16 s) confirmed that
the loss of these peaks was not an artifact of relaxation times –
components with long spin–lattice relaxation would be sup-
pressed in experiments with short relaxation delays between
scans. The loss of bisoprolol signals could also be associated
with a dramatic increase in molecular mobility, which would
selectively reduce the efficiency of cross-polarization for mo-
bile components. However, direct excitation of the 13C spec-
trum, using recycle delays of up to 50 s, did not reveal signals
from mobile components that could be assigned to bisoprolol.
To investigate the apparent disappearance of the bisoprolol
signals in the 50/50 physical mixture spectrum, the intensities
of the methyl (C-1, 14.1 ppm) resonance of valsartan and the
alkyl signal at 72.9 ppm of bisoprolol in the binary mixture
were measured as a function of the cross-polarization contact
time, Fig. 8. The slope of decaying part of the curve, which
corresponds toT1ρ relaxation, is similar for both carbons. This
is consistent with them being mixed at a molecular level or in
domains smaller than 5 nm (34) and also shows that the
weakness of the bisoprolol signals is not due to rapid T1ρ
relaxation during cross-polarization. The bisoprolol signals
are present, but just very weak and broad, presumably as a
result of the distribution of local environments and hence
dispersion of chemical shifts for each resonance due to
amorphisation.
Figure 9 shows the X-ray diffraction patterns of crystalline
and quench-cooled bisoprolol as a function of temperature.
The diffraction patterns of the crystalline material at 60 and
80°C show only modest changes of peak intensity and no
significant changes in peak position, suggesting that there is
no significant structural change during heating, which agrees
with the DSC and NMR findings. XRPD of the quench-
cooled bisoprolol at 0°C, i.e. below the re-crystallization
f
e
d
c
b
a g
h
i
j
Fig. 6 13C CPMAS NMR spectra of (a–e) crystalline, (f) melted then cooled to 80°C in the rubbery state and (g–j) quench-cooled bisoprolol as a function of
calibrated temperature.
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temperature, shows a characteristic halo pattern confirming
its amorphous nature. At 60°C, the material has re-
crystallized into the same form as the starting material. How-
ever, the diffraction peaks are much weaker, suggesting a
lower degree of crystallinity. This is consistent with the lower
melting point of bisoprolol in the second heating and the
slightly broader and less-resolved NMR resonances of
quench-cooled bisoprolol at 60°C, Fig. 6i.
XRPD patterns of the 50/50 physical mixture, Fig. 10,
show peaks corresponding to bisoprolol at 25°C. Although
some studies suggest that the lack of observed interactions via
XRPD at ambient temperature proves that DSC is a more
sensitive technique (27, 53), variable-temperature XRPD ex-
periments are necessary in order to meaningfully compare the
two methods. A decrease of signal intensity from the crystal-
line bisoprolol component starts at about 60°C (data not
shown), and at 80°C the XRPD pattern implies that the
material is fully amorphous. In the second heating, the amor-
phous halo observed from 0 to 60°C confirms that the mate-
rial remains amorphous (data not shown), as found by other
methods. In contrast to the solid-state NMR results on 70/30
and 80/20 mixtures, but in agreement with DSC, XRPD
measurements on the 70/30 physical mixture showed only
partial amorphisation of bisoprolol, with some of bisoprolol
remaining in its crystalline state (Figure 3S, supplementary
material).
To investigate the potential involvement of the COOH
and NH groups in the interaction between the drugs, 1H
MAS NMR studies were also performed using very fast
magic-angle spinning (53 kHz) to reduce the line-broadening
Fig. 8 13C NMR signal intensity vs. cross-polarization contact time for the
CH3 at 14.1 ppm of valsartan and the alkyl signal at 72.9 ppm of bisoprolol in
their 50/50 (w/w) physical mixture at 80°C.
e i
h
g
f
d
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a
Fig. 7 13C CPMAS NMR spectra of each API and physical mixtures in different concentrations at 38 and 80°C.
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associated with the strong dipolar interactions between 1H
spins (54). Four different resonances are distinguishable in the
fast MAS 1H spectrum of bisoprolol, Fig. 11a, corresponding
to methyl (≈0.7 ppm), methylene, methine, hydroxyl, amine
(2–5.5 ppm), aromatic (≈7 ppm) protons and also a low
intensity signal at≈10.4 ppm corresponding to an acid proton
bonded to amine group. Figure 11b and c show spectra of the
two valsartan forms, clearly showing differences in the hydro-
gen bonding region at 12–18 ppm. Figure 11d shows spectra
of physical mixture of both APIs (solid line) and the sum of
spectra of the pure materials (dashed line) The lines of the
physical mixture are slightly sharper than the sum spectrum,
confirming increased mobility at the onset of transition; in-
creasing the spinning rate of the sample of untreated physical
mixture to 63 kHz resulted in the sample volume expanding,
presumably as the increased frictional heating triggered the
interaction at about 60–80°C. This volume expansion is con-
sistent with the crystalline bisoprolol transforming into an
amorphous form with lower density. Figure 11e shows the
spectra of the physical mixture heated in an oven to 80°C and
cooled to room temperature. The lines are now significantly
sharper than the spectrum of the pure materials, due to
increased molecular mobility in the amorphised material.
The spectrum also shows changes in the hydrogen bonding
region i.e. in acidic and tetrazole protons signals arising from
valsartan, which implies a change of hydrogen bonding due to
amorphisation and/or deprotonation of these acidic carbons.
The differences in overall mobility were confirmed by static
1HNMR; the bandshape of untreated physical mixture is
measurably broader (Δυ½=37.6 kHz) then that from the
mixture heated to 80–85°C and recorded at room tem-
perature (Δυ½=28.9 kHz), consistent with increased
Fig. 9 Variable-temperature X-ray
diffractograms of (a) crystalline and
(b) quench-cooled bisoprolol.
Fig. 10 X-ray diffractograms of
crystalline bisoprolol, amorphous
valsartan (form AR) and a 50/50
(w/w) physical mixture of
bisoprolol/valsartan (form AR) at (a)
25°C and (b) 80°C.
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Fig. 11 1H MAS NMR spectra of (a) bisoprolol, (b) valsartan (form AR), (c) valsartan (form AM), (d) 50/50 physical mixture of bisoprolol/
valsartan (solid line) (e) 50/50 physical mixture of bisoprolol/valsartan heated to 80°C (solid line). (d) and (e) show also the sum spectra of valsartan and bisoprolol
(dashed line). Spectra were recorded at anMAS rate of 53 kHz. Sharper resonances in physical mixtures indicate increased mobility (amorphisation) of the mixture
(d–e).
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motion in the amorphised material (Figure 4S, supple-
mentary material).
To further investigate the nature of the interactions, 1D
and 2D solution-state NMR experiments were performed.
Although there is a report related to degradation of bisoprolol
in acidic environments (55), spectra of untreated and heated to
80°C bisoprolol/valsartan physical mixtures do not show
significant differences, indicating no significant degradation
after heating the sample to the interaction temperature (80°C)
and holding the mixture at this temperature for 10–15 min.
Comparing the spectra of bisoprolol fumarate in isolation and
in its physical mixture reveals some significant differences in
1H and 13C chemical shifts, Table I. These differences are
largest for nuclei close to the amine group. For example, the
methyl carbons (C-17, C-18) show increased shifts of
0.09 ppm for 1H and 1.6–1.9 ppm for 13C, while the methy-
lene carbon (C-15) shift is 1.4 ppm lower in the mixture with
valsartan. The fumarate carboxylic carbons (C-22, C-19)
shifts also change significantly (ΔδC=−1.9 ppm), implying a
change in association of the fumarate ions. Comparing the
valsartan spectra is more difficult due to the presence of two
conformers in solution associated with hindered rotation of its
amide bond, see Refs. (56, 57). Changes are seen for the
carbonyl group (C-5) and in the aromatic region (Table IS,
supplementary material). These are associated with changes of
conformational distribution of valsartan due to interaction
with bisoprolol, and are not discussed further in this paper.
There is also a noticeable change in shift of the carboxylic
carbon (C-10, ΔδC=−0.55 and −0.61 ppm for the major and
minor conformer, respectively). Similar information was pro-
vided by FT-IR spectroscopy (Figure 5S, supplementary
material).
More direct evidence of interaction between valsartan and
bisoprolol fumarate is provided by the diffusion ordered spec-
troscopy (DOSY) experiments, Figure 6S of the supplemen-
tary material. In D2O solution, the fumarate species has a
significantly faster diffusion rate (by a factor of 1.5) than the
bisoprolol, as would be expected from its much smaller mo-
lecular mass and size, Figure 6S(A). In DMSO solution,
however, the diffusion rates of fumarate and bisoprolol are
similar (DF=1.746 (±0.006)×10
−10 m2 s−1 and DB=1.865
(±0.005)×10−10 m2 s−1), implying that they diffuse as an ion
pair; this pairing is disrupted in D2O solution, which allows
the fumarate to diffuse more freely, Figure 6S(B). The pres-
ence of valsartan has a similar effect in the DMSO solution,
Figure 6S(C); the valsartan and bisoprolol species migrate at
the similar rate (DB=1.52 (±0.01)×10
−10 m2 s−1 and DVAL=
1.552 (±0.007)×10−10 m2 s−1), with the fumarate diffusing
23% faster than bisoprolol. This strongly suggests that the
valsartan and bisoprolol are preferentially associating, leaving
the fumarate species to diffuse more quickly. Although the
behaviour of molecules in solution cannot be directly com-
pared to their behaviour in the solid state, these observations
are consistent with the disruptive effects of valsartan on the
crystalline bisoprolol fumarate.
DISCUSSION
Bisoprolol fumarate is found to have glass transition below
room temperature (−3.6°C) and to be unstable in amorphous
form, undergoing re-crystallization upon heating to the same
polymorphic form as starting material but probably with a
lower degree of crystallinity.
Knowing the glass-forming ability of APIs from their crys-
talline state is very important for development of the solid
dosage form. Amorphous solid forms usually show improved
solubility. The solubility improvement of amorphous form is
not relevant to bisoprolol as it is freely soluble, but formation
of amorphous API might increase the rate of chemical degra-
dation and cause problems during manufacturing (42, 58).
Baird et al. (59) divided the crystallization tendency of drug
into 3 classes. Drugs showing only a crystallization peak (Tc)
and no glass transition (Tg) signal during the 1st cooling of
melted drug belong to class 1, those that do not undergo
crystallization during the first cooling but become crystalline
at aboveTg during second heating, to class 2 and those that do
not convert into crystalline form during cooling/heating/
heating cycle, to class 3. Bisoprolol fumarate is found to
belong to class 2. The crystalline form of valsartan could not
be obtained, but the thermal behavior of its amorphous form
indicates that it belongs to class 3.
Compatibility studies of crystalline bisoprolol fumarate and
two amorphous forms of valsartan (free acid) were completed
over a range of temperatures from room temperature to
above the phase transitions of both APIs. DSC and TMDSC
revealed the interaction of the APIs by the appearance of a
new peak and the disappearance of the bisoprolol melting
peak in the physical mixtures. Such lowering or shifting of
the melting peak in mixtures might occur as a result of the
formation of a eutectic mixture, which is a common phenom-
enon known for APIs (60). However, eutectics are generally
considered in terms of initially crystalline components, where-
as in this case one of the materials is amorphous, having a Tg
rather than a melting point.Moreover, the TMDSC reversing
curve does not show an endothermic melting peak, suggesting
no eutectic formation has occurred. Instead the new transition
peak appears as a kinetic signal, confirming irreversibility of
the process and indicating chemical or physical interaction.
The 13C CP MAS NMR and XRPD measurements clearly
show the interactions as the samples are heated to 80°C. The
13C NMR spectrum of the 50/50 physical mixture contained
only broad and low intensity signals, suggesting that the
bisoprolol has interacted with valsartan and amorphised. This
is consistent with the picture from XRPD. The static 1H
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bandshapes suggest increased overall mobility in the
amorphised material, while the 1H spectra obtained at ultra-
fast MAS rates showed significant changes in the signals in the
hydrogen bonding region arising from the acidic COOH and
tetrazole hydrogens of valsartan.
A likely cause of the interaction is the competition between
valsartan and fumarate for bisoprolol amine group. Valsartan
has two acidic centres, the COOH group (pKa1=3.6) and the
tetrazole ring (pKa2=4.7) (61), while bisoprolol is a salt of
bicarboxylic fumarate acid (pKa1=3.0, pKa2=4.4) (62). There
is a possibility of H+ exchange as valsartan has a lower pKa1
than pKa2 for fumaric acid. It is worth noting that valsartan as
a free acid is successfully formulated with besylate salt API
(Exforge®, amlodipine besylate), but benzenesulfonic acid is a
much stronger acid (pKa=0.70) than valsartan, and so acid–
base reaction is unlikely.
Although pKa values describe equilibrium phenomena in
solution, it is widely accepted that they can be a valuable tool
for predicting acid–base interactions in solid-state (63). It is
possible that the dominant interaction in the solid state could
be protonation of the doubly deprotonated fumarate in
bisoprolol fumarate by the acidic proton of valsartan, corre-
sponding to a 1:1 molar ratio of APIs. The mole ratios in the
investigated 20/80, 50/50, 70/30 and 80/20 (w/w)
bisoprolol/valsartan physical mixtures are as follows: 1:7.04,
1:1.76, 1:0.76, 1:0.44. 13C CP MAS NMR measurement of
50/50 mixture revealed interaction, whereas the 70/30 and
80/20 spectra showed clear resonances from bisoprolol sug-
gesting that a significant fraction of the bisoprolol fumarate
was largely unchanged. The XRPD measurements indicated
amorphisation of the mixture at 50/50 concentration, and
experiments with the 70/30 mixture showed an increased
halo pattern, confirming some amorphisation, but also some
unaltered bisoprolol fumarate diffraction peaks. In the 50/50
mixture there is enough valsartan to displace one fumarate
carboxylate, whereas in the 70/30 and 80/20 mixtures there
is excess of bisoprolol fumarate, and thus crystalline bisoprolol
can still be detected by NMR and XRPD. The TMDSC
results show similar behavior with concentration; the
non-reversing (kinetic) heat flow shows an enthalpy re-
laxation peak corresponding to valsartan AR form in
the 20/80 and 50/50 BISO/VAL physical mixtures but
not in the 80/20 mixture, where all valsartan had
“reacted”. The DSC shows evidence of the interaction
over a wide range of concentrations; the melting peak is
broadened but is observed in the physical mixtures with
90% bisoprolol concentration, while the melting peak was not
identified with 80% or less of bisoprolol in the physical mix-
ture. The results show that the addition of small amounts of
valsartan (>10%) leads to major changes in the solid state of
bisoprolol fumarate. In this respect, the DSC is more sensitive
than XRPD and NMR, which both struggle to observe low
fractions of amorphous content.
CONCLUSIONS
The crystalline and amorphous forms of bisoprolol and
its compatibility with two amorphous forms of valsartan
were analyzed. Amorphous bisoprolol has low stability
and re-crystallizes above the glass transition. The com-
patibility study has shown that simple blending of the
APIs to produce a fixed-dose formulation of bisoprolol
and valsartan is unsuitable due to physical and chemical
reaction which causes amorphisation into a new
bisoprolol/valsartan material at elevated temperatures,
and potentially also under long-term storage. Thus,
formulation of an FDC or polypill containing bisoprolol
and valsartan would require physical separation of the
ingredients to ensure a stable product. Similar problems
might be expected with excipents or APIs containing
carboxylic group; for example with aspirin or folic acid.
It was demonstrated that thermal methods play a piv-
otal role in early detection of API-API interaction lead-
ing to incompatibilities. Solution- and solid-state NMR
and XRPD provide information about the molecular
nature of these interactions. Variable-temperature
NMR and XRPD experiments are seen to be an ideal
complement to thermal methods in the investigation of
drug-drug incompatibilities as the kinetics of potential
interactions may be too slow to be detected at ambient
temperature.
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